SCHEMBL4487955

SCHEMBL4487955

Cc1[nH]c(C)c(-c2ccc(OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)nc2)c(=O)c1Cl

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.66
MRGPRX4 Q96LA9 1/20 0.37
PTGES O14684 6/20 0.37
DGAT1 O75907 7/20 0.36
PTPN1 P18031 1/20 0.35
CYP2D6 P10635 1/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
ADAMTS4 O75173 1/20 0.34
KDR P35968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4468888 0.91 SLC2A1 (0.79) SLC2A1MRGPRX4
SCHEMBL4490726 0.91 SLC2A1 (0.61) SLC2A1MRGPRX4PTGESDGAT1PTPN1
SCHEMBL4493325 0.88 SLC2A1 (0.84) SLC2A1MRGPRX4DGAT1PTPN1CYP2D6
SCHEMBL4484452 0.86 SLC2A1 (0.53) SLC2A1PTGESPTPN1
SCHEMBL4469233 0.83 SLC2A1 (0.52) SLC2A1PTGES
SCHEMBL4476493 0.83 SLC2A1 (0.52) SLC2A1PTGESCYP2D6
SCHEMBL13754686 0.83 SLC2A1 (0.56) SLC2A1
SCHEMBL4493447 0.81 SLC2A1 (0.52) SLC2A1PTGESDGAT1HDAC1HDAC8
SCHEMBL4481121 0.79 SLC2A1 (1.00) SLC2A1MRGPRX4PTPN1
SCHEMBL4476159 0.78 SLC2A1 (0.79) SLC2A1MRGPRX4DGAT1PTPN1ADAMTS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US claimed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US claimed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP SLC2A1 2278/4885MRGPRX4 1300/4885PTGES 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.